Sarepta Therapeutics Inc
(LTS:0L35)
$
121.67
0 (0%)
Market Cap: 11.61 Bil
Enterprise Value: 11.80 Bil
PE Ratio: 78.90
PB Ratio: 9.50
GF Score: 82/100 Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2021 / 05:10PM GMT
Release Date Price:
$88.82
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
Hi, everyone, and welcome to the 2021 Credit Suisse Healthcare Conference. We're thrilled to have Sarepta with us. Doug Ingram, CEO, will be conducting a fireside chat with myself. I'm Judah Frommer. I cover SMid-cap biotech here at CS.
And I'll just let the audience know, if you do have any questions for Doug, you can certainly e-mail them to me, [email protected].
Questions & Answers
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
And with that, why don't we jump right into DMD, which is going to be the topic of a conversation here. So Doug, maybe can you first just frame the current therapeutic landscape for DMD, where your marketed therapies fit and the degree of unmet need that still exists?
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director
Sure. First of all, thank you for having us. I'm here along
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot